Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
0.00 (0.00%)
Nov 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 85.78 - 106.84
Open     -
Vol / Avg. 13,752.00/1.71M
Mkt cap 231.73B
P/E 25.01
Div/yield 2.67/3.10
EPS 3.44
Shares 2.40B
Beta 0.63
Inst. own 10%
Feb 23, 2016
Novartis AG Annual Shareholders Meeting Add to calendar
Jan 27, 2016
Q4 2015 Novartis AG Earnings Release Add to calendar
Dec 3, 2015
Novartis AG at Deutsche Bank dbAccess Pharmaceutical Corporate Day Add to calendar
Dec 2, 2015
Novartis AG at Berenberg European Conference Add to calendar
Nov 25, 2015
Novartis AG at Exane BNP Paribas SRI/ESG Conference
Nov 18, 2015
Novartis AG at Jefferies Global Healthcare Conference
Nov 12, 2015
Novartis AG at Bryan Garnier European Healthcare Conference
Nov 11, 2015
Novartis AG at Credit Suisse Healthcare Conference
Nov 10, 2015
Novartis AG at UBS European Conference
Nov 4, 2015
Novartis AG at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 14.51% 20.00%
Operating margin 17.89% 20.68%
EBITD margin - 31.46%
Return on average assets 5.42% 8.53%
Return on average equity 9.31% 14.69%
Employees 120,000 -
CDP Score - 94 B


Lichtstrasse 35
BASEL, 4056
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Company's segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Joseph Jimenez Jr Chief Executive Officer, Member of the Executive Committee
Age: 55
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 69
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 49
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 58
Bio & Compensation  - Reuters
Steven Baert Head Human Resources and Member of the Executive Committee
Age: 40
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters